Abstract：
UNASSIGNED: To study the efficacy of cyclosporin 0.05% eye drops in the management of grade 1 and 2 acquired punctal stenosis and to compare the results with the clinical outcomes of mini-Monoka insertion.
UNASSIGNED: A prospective, controlled, interventional clinical study includes all patients (16 years and older) with symptomatic epiphora and diagnosed with grade 1 or grade 2 acquired punctal stenosis. All patients undergo punctal dilatation, canalicular probing, and nasolacrimal duct irrigation. Afterwards, patients are divided into two groups: Group A: patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc.) twice daily for 6 months. Group B: patients receive mini-Monoka stent insertion in the lower canaliculus for 6 weeks. Outcome measures are changes in Munk scoring, grading of the punctum, and functional and anatomical success. Functional success is defined as Munk score 0 to 1 and FDDT grade 0-2. Anatomical success is defined as grade 3 punctum.
UNASSIGNED: Forty-two patients are included in the study, with 21 patients in each group. There were no significant differences in the Munk score between the two groups before treatment; however, group B had a significantly higher mean rank at 6 months after treatment. After treatment, the punctal size was significantly larger in group B at 4 weeks and 3 months. However, no significant difference in punctal size was detected at 6 months after treatment between the two groups.
UNASSIGNED: Application of cyclosporin 0.05% eye drops is a simple and efficient non-interventional method in the management of grade 1 and 2 acquired punctal stenosis.
UNASSIGNED: A prospective, controlled, interventional clinical study includes all patients (16 years and older) with symptomatic epiphora and diagnosed with grade 1 or grade 2 acquired punctal stenosis. All patients undergo punctal dilatation, canalicular probing, and nasolacrimal duct irrigation. Afterwards, patients are divided into two groups: Group A: patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc.) twice daily for 6 months. Group B: patients receive mini-Monoka stent insertion in the lower canaliculus for 6 weeks. Outcome measures are changes in Munk scoring, grading of the punctum, and functional and anatomical success. Functional success is defined as Munk score 0 to 1 and FDDT grade 0-2. Anatomical success is defined as grade 3 punctum.
UNASSIGNED: Forty-two patients are included in the study, with 21 patients in each group. There were no significant differences in the Munk score between the two groups before treatment; however, group B had a significantly higher mean rank at 6 months after treatment. After treatment, the punctal size was significantly larger in group B at 4 weeks and 3 months. However, no significant difference in punctal size was detected at 6 months after treatment between the two groups.
UNASSIGNED: Application of cyclosporin 0.05% eye drops is a simple and efficient non-interventional method in the management of grade 1 and 2 acquired punctal stenosis.
摘要：
■研究0.05％环孢菌素滴眼液治疗1级和2级获得性泪点狭窄的疗效，并将结果与mini-Monoka插入的临床结果进行比较。
■预期，控制,介入性临床研究包括所有有症状的泪点溢出且诊断为1级或2级获得性泪点狭窄的患者(16岁及以上).所有患者都接受了泪点扩张术,泪管探查,和鼻泪管冲洗。之后,患者分为两组：A组：患者仅接受局部0.05％环孢菌素形式的药物治疗（Restasis®，AllerganInc.）每天两次，持续6个月。B组：患者在下小管接受微型Monoka支架插入6周。结果指标是Munk评分的变化，泪点的分级，以及功能和解剖学上的成功。功能成功定义为Munk评分0至1，FDT评分0-2。解剖成功定义为3级泪点。
■42名患者被纳入研究，每组21例。两组患者治疗前的Munk评分无显著差异;治疗后6个月，B组的平均排名明显高于对照组。治疗后,B组的泪点大小在4周和3个月时显著增大.然而,两组治疗后6个月的泪点大小无显著差异.
■在1级和2级获得性泪点狭窄的管理中，应用环孢菌素0.05％的滴眼液是一种简单有效的非干预性方法。
■预期，控制,介入性临床研究包括所有有症状的泪点溢出且诊断为1级或2级获得性泪点狭窄的患者(16岁及以上).所有患者都接受了泪点扩张术,泪管探查,和鼻泪管冲洗。之后,患者分为两组：A组：患者仅接受局部0.05％环孢菌素形式的药物治疗（Restasis®，AllerganInc.）每天两次，持续6个月。B组：患者在下小管接受微型Monoka支架插入6周。结果指标是Munk评分的变化，泪点的分级，以及功能和解剖学上的成功。功能成功定义为Munk评分0至1，FDT评分0-2。解剖成功定义为3级泪点。
■42名患者被纳入研究，每组21例。两组患者治疗前的Munk评分无显著差异;治疗后6个月，B组的平均排名明显高于对照组。治疗后,B组的泪点大小在4周和3个月时显著增大.然而,两组治疗后6个月的泪点大小无显著差异.
■在1级和2级获得性泪点狭窄的管理中，应用环孢菌素0.05％的滴眼液是一种简单有效的非干预性方法。
